Generate Biomedicines
Public companyUS1 field
Where it works
| Technology | ||
|---|---|---|
| Synthetic biologyDesigns protein and antibody drugs with generative AI; listed on Nasdaq as GENB. | Designs protein and antibody drugs with generative AI; listed on Nasdaq as GENB. | generatebiomedicines.com |
Events
| Date | Event | ||
|---|---|---|---|
| Feb 26, 2026 | Generate Biomedicines prices $400M Nasdaq IPOgeneratebiomedicines.com· Deal· Synthetic biology | Synthetic biology | Deal |
| Dec 1, 2025 | Generate Biomedicines to start Phase 3 studies of AI-engineered asthma antibodygeneratebiomedicines.com· Milestone· Synthetic biology | Synthetic biology | Milestone |
Funding
| Date | Round | Amount | |
|---|---|---|---|
| Feb 26, 2026 | IPO | $400M | generatebiomedicines.com |
About
- Source
- generatebiomedicines.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Sep 25, 2026
| Date | Change | ||
|---|---|---|---|
| Sep 25, 2026 | Generate BiomedicinesCompany in Synthetic biology: Joined a field, Designs protein and antibody drugs with generative AI; listed on Nasdaq as GENB. | seed | generatebiomedicines.com |
| Sep 25, 2026 | Generate BiomedicinesCompany: Added | seed | generatebiomedicines.com |